Kornimate/medical-research-clean huggingface dataset:
magnevist® injection-enhanced mra compared to non contrast mra for the detection of stenosis of the renal arteries

Conditions: Renal Artery Stenosis

Summary: the purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of magnevist (the study drug) used for mri of the renal arteries. the results will be compared to the results of mri taken without magnevist and with the results of your x-ray angiography.

this study has previously been posted by berlex, inc. berlex, inc. has been renamed to bayer healthcare pharmaceuticals, inc.bayer healthcare pharmaceuticals, inc.is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: - has known or suspected renal artery disease - is scheduled for x-ray angiography exclusion criteria: - has any contraindication to magnetic resonance imaging - is scheduled for any procedure before the x-ray angiography - had previously had stents placed bilaterally in the region to be imaged
study to assess a radiofrequency microneedling device for dermatologic conditions

Conditions: Wrinkle; Fine Lines; Crepey Skin; Acne Scars; Acne; Enlarged Pores; Stretch Marks; Loose Skin

Summary: subjects are to be enrolled in this clinical study if they are 18 - 55 years old. up to 120 subjects will be enrolled at multiple study centers. subjects may receive up to 5 treatments for a wide array of dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.


Eligibility criteria:
inclusion criteria: * a healthy, non-smoking male or female between the age of 18-55 years old. * fitzpatrick skin type i to vi. * understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study. * understands and accepts the obligation and is logistically able to be present for all visits. * is willing to comply with all requirements of the study and sign the informed consent document. exclusion criteria: * is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study. * the subject is currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months prior to entering this study. * the subject has physical problems such as cardiovascular disorders. * the subject has a pacemaker. * the subject had previous use of gold thread skin rejuvenation. * the subject has skin infections. * the subject has any of the following conditions: * diabetes * epilepsy * acute disease * dermatitis * subjects with electronic implants such as cardiac defibrillator. it may interfere with operation of electronic implants or damage the implants, causing risks. * the subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.
tobi to monitor response to neoadjuvant therapy in breast cancer

Conditions: Breast Cancer

Summary: the purpose of this research study is to see if near-infrared tomographic optical breast imaging (tobi) scans can help monitor breast tumor response during treatment for breast cancer. the images created by the tobi scan show changes in blood blow and oxygen levels in breast tissue.

* participants will have a tobi scan prior to starting their cancer treatment and again on day 8 after their first treatment. participants will also be asked if they would volunteer to undergoing one or more additional tobi scans on days 2-7 after they begin cancer treatment. these additional scans are optional. participants will also have a scan on the first day of each treatment cycle. * tobi scans will be performed at the gillette center for breast cancer at the massachusetts general hospital. * for the scan, each breast is placed between 2 plastic plates in order to spread the tissue apart, similar to the procedure for a mammogram. the tobi scanner is attached to these plates. we will apply mild pressure to compress the breast and the breast will be scanned using light waves. each scan will take about 3 minutes.

Eligibility criteria:
inclusion criteria: * adult female patients presenting to the mgh cancer center gillette center for breast cancer neoadjuvant therapy * subject who have had or will have a clinically indicated pre-treatment breast mri exclusion criteria: * younger than 18 years of age * open wounds on breast * breast implants, because they may interfere with readings * subjects who will be receiving preoperative therapy for \<28 days * breast surgery or biopsy \< 10 days prior to optical imaging scan * medical or psychiatric or other medical condition that the principal investigator believes may result in inability to complete the study * bilateral breast cancers or a history of contralateral breast cancer

Keywords: neo-adjuvant chemotherapy tobi breast imaging optical imaging
a study of ov101 in individuals with angelman syndrome (as)

Conditions: Primary Disease or Condition Being Studied: Angelman Syndrome (AS)

Summary: the purpose of this study is to assess the efficacy and safety of oral ov101 (gaboxadol) in pediatric subjects with angelman syndrome.


Eligibility criteria:
inclusion criteria: * male or female and 2 to 12 years old (inclusive) at the time of informed consent * confirmed molecular diagnosis of as * has a cgi-s-as score of 3 or more at baseline. * meets the following age-appropriate body weight criterion: 1. subjects 2 to 3 years old must have a minimum body weight of 9 kg. 2. subjects 4 years and older must be between 17 kg and 64 kg (inclusive). * stable concomitant mediations for at least 4 weeks before study start exclusion criteria: * any condition that would limit study participation * clinically significant lab or vital sign abnormalities at the time of screening * poorly controlled seizures (weekly seizures of any frequency with a duration more than 3 minutes, weekly seizures occurring more than 3 times per week, each with a duration of less than 3 minutes, or as defined by investigator assessment) * use of prescription medications for sleep, minocycline, or levodopa within the 4 weeks prior to day 1 or during the study. benzodiazepines chronically administered for seizure control are permitted. * cannot comply with protocol study assessments during screening or caregiver unable to comply with study requirements. * enrolled in any clinical trial or used any investigational agent within the 30 days before screening or concurrently with this study.
antenatal palliative care

Conditions: Fetal Death; Fetal Anomaly

Summary: in france, according to current legislation, termination of pregnancy could be performed without any upper gestational age limit, if there is a strong probability that the fetus will be affected by a particularly severe and incurable disease. when there is a lethal fetal diagnosis most of parents wish to terminate their pregnancy. however, and despite some medical resistance a few of them do wish to continue pregnancy. in these situations, palliative care seems to be a good way to prepare to welcome the child and surround him until death. the aim of the study is to describe parents' experience for a better understanding and a better care.


Eligibility criteria:
inclusion criteria: * the woman must be between the ages of 18 and 50 and the adult, * participants must have received the information and not have objected to participating in the study, * the lethal / adverse short-term prognosis of the fetal pathology must have been confirmed by a committee of experts (cpdpn), * the choice to continue the pregnancy should have been clearly expressed, * the birth of the child should not be older than 24 months. * the child's death must be more than 6 months old (or not have occurred) exclusion criteria: * non-mastery of the french language, * measure of legal protection of one of the members of the couple (guardianship, trusteeship, ...), * severe psychiatric or neurological disorders inducing significant cognitive impairment.
bladder and prostate sonomorphology in patients with symptomatic benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia

Summary: bladder and prostate sonomorphology in patients with symptomatic benign prostatic hyperplasia?

bladder and prostate sonomorphology as a useful tool for detecting bladder outlet obstruction in patients with symptomatic benign prostatic hyperplasia?

Eligibility criteria:
inclusion criteria: male patients with luts/bph prostate size \> 25 g exclusion criteria: urinary retention diabetes mellitus neurologic deficit luts medications prior lower urinary tract surgery concomitant bladder pathology small bladder capacity (\< 150 ml) urethral stricture evident prostate carcinoma.
subacute effect of tolvaptan on total kidney volume in adult patients with autosomal dominant polycystic kidney disease

Conditions: Autosomal Dominant Polycystic Kidney

Summary: investigator initiated controlled multi-centre trial in a prospective, randomised, open, blinded endpoint (probe) design. patients will be randomised in a 1:1 ratio either to treatment with tolvaptan for six weeks followed by six weeks observation without trial medication or no tolvaptan treatment, but following the same visit and investigation plan as the subjects taking tolvaptan.

autosomal dominant polycystic kidney disease (adpkd) is the most common genetic kidney disease and the fourth leading cause of end-stage renal disease in adults worldwide. the tolvaptan tablet has been approved by ema (european medicines agency) with the indication of slowing the progression of cysts development and renal insufficiency in adults with adpkd. it is the newest and only possible treatment for this patient group and could be initiated in patients with evidence for rapidly progressive disease development. there is however in denmark and other countries both scientific and financial reluctance to initiate this expensive treatment for several reasons e.g. selection of patients who might benefit, effect on progression of kidney disease, side effects and tolerability. before deciding on implementation in denmark, more knowledge is needed. the results of the pocket trial will contribute with guidance on this decision. foremost the trial is designed to address not only the change in kidney volume, but the change in kidney function, which is what matters to the patients and their prognosis in terms of postponing time to end stage renal disease. furthermore, important data on side effects and tolerability will be generated.

Eligibility criteria:
inclusion criteria: * adult patients between 18 and 65 years * diagnosis of typical adpkd * tkv above or equal to 750 ml by mri scanning * estimated gfr (e-gfr) by ckd-epi formula of above or equal to 45 ml/min/1.73 m2 exclusion criteria: * kidney transplant recipient * known liver disease except for liver cysts relating to adpkd * asat and alat above upper normal level * current treatment with thiazide and thiazide-line diuretics, mineral corticoid receptor antagonists, amiloride or loop diuretics * evidence of urinary tract obstruction * current treatment with cyp3a4 inhibitors * active malignant disease * current or previous treatment with tolvaptan
investigating the regulation of reproductive hormones in adult men

Conditions: Kallmann Syndrome; Hypogonadism; Gonadal Disorder

Summary: the purpose of the research study is to learn more about the regulation of reproductive hormones in adult men. we would like to understand what role testosterone and estradiol play in controlling the release of lh (lutenizing hormone) and fsh (follicle stimulating hormone). testosterone and estradiol come from the testes, and lh and fsh are released from a gland in the head called the pituitary. men involved in the study will have detailed evaluations that involve overnight stays in the hospital and frequent blood sampling. the men in the study will also be receiving medications that affect the levels of various hormones in the body. this will allow the researchers to learn how various hormones influence each other. men that participate in the study will receive medical evaluations and monetary compensation. information gathered from this study will help in the development of new treatments for infertility and potentially new hormonal forms of contraception.

in the united states 10-15% couples seek evaluation for infertility, of whom a male factor is identified in approximately 50% of cases. to date, however, most infertility research has focused on the female partner and in the majority of instances the etiology of male infertility remains poorly understood with inconsistent elevation in fsh levels. given that spermatogenesis is highly dependent on fsh secretion, this project will focus on delineating the feedback control of fsh in the human male. such studies, although difficult to perform in the human, are critical to understanding not only the pathophysiology of male infertility, but also to determining the feasibility of hormonal approaches to male contraception. in this protocol, studies of normal, gnrh-deficient and agonadal men employing reversible sex steroid ablation, physiologic sex steroid replacement and manipulation of the gnrh input to the pituitary will permit the non-steroidal, sex steroid, and gnrh-dependent components of fsh regulation to be selectively elucidated.

Eligibility criteria:
inclusion criteria: * men aged 18 to 50 years * in good health * on no medications exclusion criteria: subjects will not be enrolled in this study if there is a history of: * liver disease or if screening blood tests demonstrate abnormal liver function tests * excessive alcohol consumption * illicit drug use * severe drug allergy * use of any concomitant medications * peptic ulcer disease or gastritis

Keywords: idiopathic hypogonadotropic hypogonadism kallmann syndrome agonadal
alzheimer's disease: therapeutic potential of estrogen

Conditions: Alzheimer Disease

Summary: this is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with alzheimer's disease.

estrogen is a naturally occurring hormone produced in a woman's body. the purpose of this 15-month study is to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with alzheimer's disease and without other dementias. patients who volunteer for this study will either receive a patch containing 17-ß-estradiol or will receive an inactive placebo patch. in addition, patients will be given either medroxyprogesterone or an inactive placebo pill. neither the volunteers nor the study staff will know which type of patch or pill a patient receives. patients must be generally healthy and have mild-to-moderate dementia. there must be a patient caregiver who can watch for side effects and ensure that the patient takes the study medications on schedule. patients will undergo neuropsychological tests and an evaluation of the ability to live independently at each visit as well as laboratory evaluations, such as the taking of blood. each visit will last approximately 3 hours. a total of 160 participants are being recruited.

Eligibility criteria:
inclusion criteria: * postmenopausal women with alzheimer's disease and without other dementias (diagnosed by study staff or from an outside clinic) * mini mental state examination score greater than 15/30 exclusion criteria: * history of cancer of reproductive tissues * history of deep vein thrombosis or blot clots * diabetes * heart disease or stroke * liver problems including hepatitis * severe vision or hearing problems * tobacco use * lack of an adequate caregiver * inability to perform psychometric testing

Keywords: alzheimer disease hormone replacement therapy postmenopausal women
optimal dose of acetylsalicylic acid after coronary artery bypass grafting

Conditions: Coronary Artery Bypass Surgery; Stable Angina

Summary: this is a single-center, open-label, randomized controlled trial. patients with stable angina pectoris without use of dual antiplatelet therapy or anticoagulation therapy scheduled for coronary artery bypass grafting (cabg) at karolinska university hospital in stockholm, sweden will be eligible. this study investigates in patients having undergone cabg whether increasing the dose or the frequency of acetylsalicylic acid (asa) treatment improves the efficacy of asa regarding platelet inhibition compared to the standard dosing for cardiovascular prevention (75 mg once daily) in the first three months after surgery. patients will be randomly assigned to postoperative asa dose 75mg once daily, 75mg twice daily or 160 mg once daily. the study dose asa will be started at hospital discharge and continued of three months. blood samples for serum thromboxane b2 (txb2) and other analyses will be taken before surgery, before discharge, and after one and three months. all available data will be collected prospectively. informed consent will be obtained from patients meeting the inclusion criteria before the initiation of any study-specific procedures.


Eligibility criteria:
inclusion criteria: * stable coronary artery disease * ≥18 years of age * scheduled to undergo elective cabg surgery * willing to participate and able to provide informed consent exclusion criteria: * intake of drugs other than asa that are known to influence platelet function, including nonsteroidal anti-inflammatory drugs (nsaids, including cox-2 selective anti-inflammatory drugs), gpiibiiia inhibitors, clopidogrel, dipyridamole, warfarin or acenocoumarol within 7 days of enrolment * hemorrhagic diathesis or known platelet dysfunction * chronic renal failure requiring dialysis * platelet count outside the 100 000 to 450 000/μl range * haemoglobin \< 8g/dl
evaluation of clinical and radiographic outcomes of meniscal lesion treatment using collagen scaffolds (cmi)

Conditions: Meniscal Degeneration; Osteoarthritis of Knee; Meniscus Injury

Summary: meniscal lesions represent the most frequently encountered joint pathology in the adult population and can cause pain symptoms, mechanical blockages, and recurrent effusions. the treatment of these lesions has progressively evolved from meniscectomy (removal of the damaged meniscal tissue) to the use of meniscal sutures (where possible) to preserve as much meniscus as possible. numerous studies have demonstrated a correlation between the amount of meniscus removed and the future onset of osteoarthritis. however, in some cases, especially in the presence of complex and/or chronic lesions, meniscectomy remains the only viable surgical option. over time, months or years later, a subgroup of patients may develop symptoms such as pain, joint swelling, and mechanical overload of the compartment that underwent meniscectomy, a condition known as post-meniscectomy syndrome..a portion of these patients will later develop knee osteoarthritis and require invasive procedures such as partial or total knee replacement. in an attempt to treat this condition, scaffolds-collagen implants-have been developed and are arthroscopically implanted in the knee with the aim of functionally replacing the tissue removed during surgery. the goal is to reduce the incidence of long-term osteoarthritis and, consequently, the need for more invasive procedures. to date, no study has definitively demonstrated the real efficacy of these scaffolds (cmi), particularly regarding chondroprotection and the long-term onset of osteoarthritis.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 65 years at the time of surgery * both male and female patients * patients who underwent meniscectomy and/or cmi implantation from january 1, 1998 to december 31, 2010 at the rizzoli orthopedic institute. exclusion criteria: * patients who are no longer reachable; * patients who do not consent to be included in the study; * presence of infection or hematological, rheumatic, or hemostatic disorders at the time of evaluation.
an evaluation of just court in yuma county, az

Conditions: Substance Abuse; Adolescent Behavior; Juvenile Delinquency Unspecified

Summary: arizona has created a pilot program for juvenile probationers called juveniles under supervision and treatment (just), which includes swift and certain, but modest responses, to technical violations of the terms of juvenile probation. just targets high- and medium-risk juvenile probationers and its stated objective is to reduce violations and overall incarceration of youth in the program. the just pilot is being implemented under the authority of the arizona governor's office for children, youth and families (gocyf) and the administrative office of the courts (aoc).

arizona's juveniles under supervision and treatment (just) court is a pilot project initiated by the arizona governor's office. it is designed to test whether the principles of swift, certain, and fair (scf) supervision-clear rules, close monitoring, and swift and certain, but modest, penalties for each violation can succeed when applied to juveniles under community supervision. the arizona administrative office of the courts piloted just in two counties: yavapai and yuma. the yuma program was launched in march 2011. the goal of just is to (a) reduce the violation rate so as to reduce the number of petitions filed to revoke probation (the purpose is to reduce the use of juvenile detention), and (b) reduce recidivism overall. all juveniles in yavapai are supervised under just (evaluation using an rct is therefore unfeasible). just in yuma is now being scaled up, which affords the opportunity for an rct. the goal of the rct is to compare the performance of youth supervised under just with those supervised under probation-as-usual.

Eligibility criteria:
inclusion criteria: * newly probated * at least 13 years old * no older than 17 years and 3 months * at least nine months remaining on supervision * must be on standard probation with a supervision level of moderate to maximum * must be able to participate in the program for at least nine months exclusion criteria: * not meeting all inclusion criteria * sex offender * dangerous offenses